Ernexa Therapeutics Inc. (ERNA) › Shares OutstandingErnexa Therapeutics Inc. (ERNA) — Shares OutstandingAnnual figures by period end, from SEC filings.2010-12-31: 60.8K2011-12-31: 60.9K2012-12-31: 71.12M2013-12-31: 78.65M2014-12-31: 92.37M2015-12-31: 1.85M2016-06-16: 92.44M2016-12-31: 2.26M2017-12-31: 2.52M2018-12-31: 2.88M2019-12-31: 2.90M2020-12-31: 02021-12-31: 2.60M2022-12-31: 5.13M2023-12-31: 5.41M2024-10-29: 51.39M2024-12-31: 3.43M2025-12-31: 7.85M7.85M2010-12-31Shares Outstanding (shares)2025-12-31Period endedShares OutstandingChange YoYSource filing2025-12-317.85M+129.2%2026-03-13Balance as of period end2024-12-313.43M—2026-03-13Balance as of period end2024-10-2951.39M—2025-03-12Balance as of period end2023-12-315.41M+5.5%2025-03-12Balance as of period end2022-12-315.13M+97.1%2024-03-14Balance as of period end2021-12-312.60M—2023-03-20Balance as of period end2020-12-310-100.0%2022-07-01Balance as of period end2019-12-312.90M+0.9%2021-03-11Balance as of period end2018-12-312.88M+14.0%2020-03-19Balance as of period end2017-12-312.52M+11.5%2019-03-22Balance as of period end2016-12-312.26M—2018-03-09Balance as of period end2016-06-1692.44M—2018-03-09Balance as of period end2015-12-311.85M-98.0%2017-03-09Balance as of period end2014-12-3192.37M+17.4%2016-03-15Balance as of period end2013-12-3178.65M+10.6%2015-03-27Balance as of period end2012-12-3171.12M+116634.8%2014-03-31Balance as of period end2011-12-3160.9K+0.3%2013-03-29Balance as of period end2010-12-3160.8K—2012-03-30Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresDividends Per ShareWeighted Average Diluted SharesEPS (Basic)